View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Virbac:: Paul Martingell's compensation terms

Virbac:: Paul Martingell's compensation terms The board of directors of Virbac specifies Paul Martingell's compensation terms as chief executive officer. The board of directors, acting upon the recommendation of the appointments and compensation committee, has approved the compensation terms for Paul Martingell for the duration of his mandate, as detailed below. In accordance with applicable regulations, Paul Martingell's compensation elements will be submitted for the approval of the shareholders ("ex ante" and "ex post" votes). Fixed compensationThe board of directors has set Paul Martin...

 PRESS RELEASE

VIRBAC: Informations sur les conditions de rémunération de Paul Martin...

VIRBAC: Informations sur les conditions de rémunération de Paul Martingell Le conseil d’administration de Virbac précise les conditions de rémunération de Paul Matingell en qualité de directeur général. Le conseil d’administration a arrêté, sur recommandation du comité des nominations et des rémunérations, les conditions de rémunération de Paul Martingell pour la durée de son mandat, telles que précisées ci-après. Conformément aux règles applicables, les éléments de rémunération de Paul Martingell seront soumis au vote des actionnaires (vote "ex ante" et vote "ex post"). Rémunération fixe...

Abivax: 1 director

A director at Abivax sold after exercising options/sold 1,104,640 shares at 54.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...

Martial Descoutures
  • Martial Descoutures

Abivax : A well-deserved success, Outperform confirmed

We are significantly raising our TP from € 24 to € 88 following the positive results of the phase 3 induction trial (ABTECT) for obefazimod in ulcerative colitis. Obefazimod achieved significant clinical remission rates higher than those observed in phase 2b, and comparable to the best agents under development. Based on these results, we believe that Abivax is a credible M&A target for a pharma player looking to strengthen its position in immunology. Outperform rating reiterated.

Martial Descoutures
  • Martial Descoutures

Abivax : Un succès bien mérité, Surperformance confirmée

Nous relevons significativement notre OC de 24 € à 88 € suite aux résultats positifs de la phase 3 (ABTECT) en induction d’obefazimod dans la rectocolite hémorragique. Obefazimod a atteint des taux de rémission clinique significatifs supérieurs à ceux observés en phase 2b, et comparables aux meilleurs agents en développement. Suite à ces résultats, nous croyons qu’Abivax est une cible crédible d’acquisition pour une Pharma voulant se renforcer en Immunologie. Recommandation Surperformance réitér...

 PRESS RELEASE

Abivax Announces Closing of $747.5 Million Public Offering

Abivax Announces Closing of $747.5 Million Public Offering Abivax Announces Closing of $747.5 Million Public Offering PARIS, France, July 28, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the closing of its previously announced underwritten public offering of 11,679,400 American Depositary Shares (“ADSs”), each r...

 PRESS RELEASE

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Add...

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) PARIS, France, July 25, 2025 – 08:00 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic i...

 PRESS RELEASE

Abivax Announces Pricing of $650M (€554M) Public Offering of American ...

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the pricing of its previously announced underwritten public offering ...

 PRESS RELEASE

Abivax announces trading resumption of its ordinary shares on Euronext...

Abivax announces trading resumption of its ordinary shares on Euronext Paris Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from ...

 PRESS RELEASE

Abivax announces temporary trading halt of its ordinary shares on Euro...

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext Paris (“Eu...

 PRESS RELEASE

Abivax Announces Launch of Public Offering

Abivax Announces Launch of Public Offering Abivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the launch of an approximately $400 million underwritten public offering (representing approximately €340 million) consisting of a public offering of its Amer...

Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
 PRESS RELEASE

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Indu...

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis  Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis   50 mg once-daily dose of obefazimod led to a compelling pooled 16.4% (p

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch